CD79A and neoplasm: Several of the top-ranked genes–MS4A1 (CD20), FCRL5 and CD79A–are closely associated with B-cell functions34–36, suggesting that variations in humoral and antigen-presenting activity may critically modulate anti-tumor immunity.